0      0

Fall Meeting 2014

090 - Trends in Pharmacology: Medicare Part D/Medical Marijuana

Oct 11, 2014 8:30am ‐ Oct 11, 2014 12:00pm


Contact hours available until 10/13/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Faculty, Planners, and Speakers Conflict of Interest Disclosure:

Planning Commitee disclosures:
• Denise Murcek - Per diem employee, Fresenius Medical Care
• Melissa Nesmith-Vester – Employee, Aegerion
• Elizabeth St. John - Employee, Fresenius Medical Care
• Kyra Trappett – Employee, DaVita

Faculty and speakers have no disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.


Laura Borgelt, PharmD, FCCP, BCPS 
• Compare and contrast regulatory issues for use of marijuana in various states.
• Describe the clinical pharmacology of marijuana and its active components.
• Explain the various dosage forms of marijuana and their pharmacodynamic impact.
• Evaluate the potential therapeutic and adverse effects of marijuana.
• Identify potential drug interactions and consumer safety issues with marijuana use.

Wendy St. Peter, PharmD, FCCP, FASN, FNKF 
• Compare and contrast Medicare Part D prescription drug program with other prescription drug coverage programs.
• Evaluate trends in medication use in CKD and ESRD patients enrolled in Part D.
• Examine overall costs of Medicare Part D program in CKD and ESRD patients, including cost burden in those do and do not receive “extra help” or those that go into the “donut hole.”
• Discuss the future of Medicare Part D, new regulations, and impact of dialysis “bundle” and potential future impact on patients and dialysis providers.


You must be logged in and own this session in order to post comments.